Legis Daily

Matt’s Act

USA116th CongressHR-7722| House 
| Updated: 7/22/2020
Jeff Fortenberry

Jeff Fortenberry

Republican Representative

Nebraska

Cosponsors (1)
Angie Craig (Democratic)

Energy and Commerce Committee, Education and Workforce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Matt's Act This bill limits the amount that private health insurance plans may charge plan holders for insulin drugs to a maximum of $20, or $0 for high deductible plans; pharmacies may charge an uninsured individual who has diabetes the average net price of such drugs after deducting any rebates and discounts provided by drug manufacturers, plus limited additional charges for distributing and dispensing costs.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jul 22, 2020
Introduced in House
Jul 22, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • July 22, 2020
    Introduced in House
  • July 22, 2020
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Health

Business recordsCongressional oversightDigestive and metabolic diseasesDrug therapyHealth care costs and insuranceHealth care coverage and accessInflation and pricesPrescription drugs

Matt’s Act

USA116th CongressHR-7722| House 
| Updated: 7/22/2020
Matt's Act This bill limits the amount that private health insurance plans may charge plan holders for insulin drugs to a maximum of $20, or $0 for high deductible plans; pharmacies may charge an uninsured individual who has diabetes the average net price of such drugs after deducting any rebates and discounts provided by drug manufacturers, plus limited additional charges for distributing and dispensing costs.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jul 22, 2020
Introduced in House
Jul 22, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • July 22, 2020
    Introduced in House
  • July 22, 2020
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jeff Fortenberry

Jeff Fortenberry

Republican Representative

Nebraska

Cosponsors (1)
Angie Craig (Democratic)

Energy and Commerce Committee, Education and Workforce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Business recordsCongressional oversightDigestive and metabolic diseasesDrug therapyHealth care costs and insuranceHealth care coverage and accessInflation and pricesPrescription drugs